Literature DB >> 12160582

Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863.

A Zurlo1, L Collette, G van Tienhoven, L Blank, P Warde, J Dubois, W Jeanneret, G Storme, J Bernier, A Kuten, M Pierart, M Bolla.   

Abstract

OBJECTIVES: We analysed the acute toxicity observed in the European Organisation for Research and Treatment of Cancer (EORTC) randomised trial 22863 comparing conventional external irradiation with or without an agonist analogue of gonadotropin-releasing hormone in high-risk prostate cancer patients.
METHODS: Four hundred five patients that received a dose of at least 30 Gy were considered evaluable for acute toxicity assessment. Toxicity was grouped in a few categories: general, genito-urinary, and lower gastro-intestinal. Univariate and multivariate analyses were performed using the World Health Organisation (WHO) toxicity score and grouping together toxicity scores in different bimodal and trimodal groups.
RESULTS: Overall, our data show that age, previous surgery and irradiation dose are important predictive factors for acute toxicity, but not the use of combined hormone therapy. Fifteen percent of patients suffered of moderate to severe acute toxicity (WHO G3-G4). Life threatening toxicity was observed in six cases (1.5%).
CONCLUSIONS: The assessment of toxicity combining in different groups the original five scores scale produced conflicting results similar to those commonly reported in literature. Interpretation of the role of pre-treatment factors with uneven distribution in the study requires careful evaluation. These data obtained with conventional curative irradiation of high-risk prostate cancer patients are proposed for comparison with results achieved using modern state-of-the-art irradiation techniques.

Entities:  

Mesh:

Year:  2002        PMID: 12160582     DOI: 10.1016/s0302-2838(02)00257-9

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  5 in total

Review 1.  Radical prostatectomy as primary treatment of high-risk prostate cancer.

Authors:  Alexandre Ingels; Alexandre de la Taille; Guillaume Ploussard
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

Review 3.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 4.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Authors:  S Kumar; M Shelley; C Harrison; B Coles; T J Wilt; M D Mason
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.

Authors:  Casey Liveringhouse; Austin Sim; Kosj Yamoah; Michael Poch; Richard B Wilder; Julio Pow-Sang; Peter A S Johnstone
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.